Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups

Blood (2023) 142 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2023-179248

Published: 2023

Journal Articles

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Blood (2017) 130 (Supplement 1): 3850.

https://doi.org/10.1182/blood.V130.Suppl_1.3850.3850

Published: 2017

Journal Articles

Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients

Fabio Efficace, PhD, Gianantonio Rosti, MD, Francesco Cottone, Laura Cannella, Marco Vignetti, MD, Franco Mandelli, MD, Massimo Breccia, MD, Michele Baccarani, MD

Blood (2016) 128 (22): 5939.

https://doi.org/10.1182/blood.V128.22.5939.5939

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life

Gregory A. Abel, Robert Klaassen, Stephanie J. Lee, Nancy L. Young, Laura Cannella, David P. Steensma, Fabio Efficace

Blood (2014) 123 (3): 451–452.

https://doi.org/10.1182/blood-2013-11-540021

Published: 2014

Journal Articles

Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.

Massimo Breccia, Roberto Latagliata, MD, Fabio Stagno, Antonella Gozzini, Elisabetta Abruzzese, Antonella Russo Rossi, Michelina Santopietro, Laura Cannella, Federica Sorà, Paolo Vigneri, Malgorzata Trawinska, Simona Sica, Giorgina Specchia, Valeria Santini, MD, Giuliana Alimena

Blood (2010) 116 (21): 3409.

https://doi.org/10.1182/blood.V116.21.3409.3409

Published: 2010

Journal Articles

Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features

Massimo Breccia, PhD, Paola Finsinger, Roberto Latagliata, MD, Laura Cannella, PhD, Giuseppina Loglisci, PhD, Mauro Nanni, PhD, Michelina Santopietro, PhD, Adriano Salaroli, PhD, Agostino Tafuri, Giuliana Alimena, PhD

Blood (2010) 116 (21): 4976.

https://doi.org/10.1182/blood.V116.21.4976.4976

Published: 2010

Journal Articles

Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation

Alessandro Sanna, MD, Laura Cannella, MD, Antonella Gozzini, MD, Massimo Breccia, MD, Francesca Sassolini, MD, Alberto Bosi, MD, Giuliana Alimena, MD, Valeria Santini, MD

Blood (2010) 116 (21): 606.

https://doi.org/10.1182/blood.V116.21.606.606

Published: 2010

Journal Articles

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Massimo Breccia, MD, Roberto Latagliata, MD, Laura Cannella, MD, Ida Carmosino, MD, Enrico Gottardi, Daniela Cilloni, MD, Marco Vignetti, MD, Michelina Santopietro, MD, Marco Mancini, MD, Giuliana Alimena, MD

Blood (2009) 114 (22): 1777.

https://doi.org/10.1182/blood.V114.22.1777.1777

Published: 2009

Journal Articles

Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.

Massimo Breccia, MD, Fabio Stagno, MD, Roberto Latagliata, MD, Paolo Vigneri, MD, Laura Cannella, MD, Ida Carmosino, MD, Vittorio Del Fabro, MD, Francesco Di Raimondo, MD, Giuliana Alimena, MD

Blood (2009) 114 (22): 3302.

https://doi.org/10.1182/blood.V114.22.3302.3302

Published: 2009

Journal Articles

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.

Paola Finsinger, Massimo Breccia, Clara Minotti, Ida Carmosino, Laura Cannella, Paola Volpicelli, Federico Vozella, Caterina Stefanizzi, Giuseppina Loglisci, Giuseppe Cimino, Robin Foà, Roberto Latagliata, MD

Blood (2009) 114 (22): 4160.

https://doi.org/10.1182/blood.V114.22.4160.4160

Published: 2009

Journal Articles

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Blood (2009) 114 (22): 648.

https://doi.org/10.1182/blood.V114.22.648.648

Published: 2009

Journal Articles

Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.

Ida Carmosino, Roberto Latagliata, MD, Massimo Breccia, Laura Cannella, Federico Vozella, Paola Volpicelli, Michelina Santopietro, Antonio Spadea, MD, PhD, Maria Concetta Petti, Giuliana Alimena

Blood (2009) 114 (22): 4985.

https://doi.org/10.1182/blood.V114.22.4985.4985

Published: 2009

Journal Articles

Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib

Roberto Latagliata, Massimo Breccia, Fabio Stagno, Silvia De Matteis, Mario Annunziata, Ida Carmosino, Laura Cannella, Laura Napoleone, Federico Vozella, Simona Sica, Francesco Di Raimondo, MD, Felicetto Ferrara, Giuliana Alimena

Blood (2008) 112 (11): 4253.

https://doi.org/10.1182/blood.V112.11.4253.4253

Published: 2008

Journal Articles

Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients

Massimo Breccia, Roberto Latagliata, Laura Cannella, Ida Carmosino, Caterina Stefanizzi, Michelina Santopietro, Giuliana Alimena

Blood (2008) 112 (11): 3983.

https://doi.org/10.1182/blood.V112.11.3983.3983

Published: 2008

Journal Articles

Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients

Massimo Breccia, Roberto Latagliata, Laura Cannella, Ida Carmosino, Caterina Stefanizzi, Michelina Santopietro, Giuliana Alimena

Blood (2008) 112 (11): 4281.

https://doi.org/10.1182/blood.V112.11.4281.4281

Published: 2008

Journal Articles

Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria

Massimo Breccia, Roberto Latagliata, Laura Cannella, Ida Carmosino, Caterina Stefanizzi, Michelina Santopietro, Giuliana Alimena

Blood (2008) 112 (11): 5097.

https://doi.org/10.1182/blood.V112.11.5097.5097

Published: 2008

NARROW

Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life

Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.

Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features

Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.

Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib

Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients

Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients

Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only